Drug Trial Radar · NCT01231620
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
Last checked: Nov 20, 2026Latest source record: Oct 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
626
Actual
Start
Jan 15, 2011
Primary completion
Mar 18, 2015
Study completion Mar 18, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 1, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu. Zanamivir will be compared with oseltamivir, which is used for treating flu.
Conditions
- Influenza, Human
Interventions
ZanamivirDrug
Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
Placebo to match zanamivirDrug
Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
OseltamivirDrug
Oseltamivir will be provided as over-encapsulated 75 mg capsules.
Placebo to match oseltamivirDrug
Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Clinical Response (TTCR) in Participants With Confirmed InfluenzaTime frame: Up to 42 days
Locations
170 sites in 28 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
Escondido, California
GSK Investigational Site
Fullerton, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
La Mesa, California
GSK Investigational Site
Oceanside, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Stamford, Connecticut
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
Sunrise, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Idaho Falls, Idaho
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Oak Park, Illinois
GSK Investigational Site
Peoria, Illinois
GSK Investigational Site
Council Bluffs, Iowa
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Royal Oak, Michigan
GSK Investigational Site
Troy, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Valhalla, New York
GSK Investigational Site
Asheville, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina
GSK Investigational Site
Bismarck, North Dakota
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Toledo, Ohio
GSK Investigational Site
Bethlehem, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Roanoke, Virginia
GSK Investigational Site
Marshfield, Wisconsin
Showing 40 of 170 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.